$9.61
3.33% today
Nasdaq, Feb 05, 04:45 pm CET
ISIN
US0465131078
Symbol
ATRA
Sector
Industry

Atara Biotherapeutics Inc Stock price

$9.30
-8.70 48.33% 1M
+1.13 13.83% 6M
-4.01 30.13% YTD
-18.45 66.49% 1Y
-355.95 97.45% 3Y
-339.95 97.34% 5Y
-515.20 98.23% 10Y
Nasdaq, Closing price Tue, Feb 04 2025
+0.78 9.15%
ISIN
US0465131078
Symbol
ATRA
Sector
Industry

Key metrics

Market capitalization $53.57m
Enterprise Value $74.31m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 0.74
P/S ratio (TTM) P/S ratio 0.53
P/B ratio (TTM) P/B ratio negative
Revenue growth (TTM) Revenue growth 2,111.34%
Revenue (TTM) Revenue $100.44m
EBIT (operating result TTM) EBIT $-119.41m
Free Cash Flow (TTM) Free Cash Flow $-94.85m
Cash position $67.34m
EPS (TTM) EPS $-25.66
P/E forward negative
P/S forward 0.48
EV/Sales forward 0.66
Short interest 11.36%
Show more

Is Atara Biotherapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,821 stocks worldwide.

Atara Biotherapeutics Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

7 Analysts have issued a Atara Biotherapeutics Inc forecast:

4x Buy
57%
3x Hold
43%

Analyst Opinions

7 Analysts have issued a Atara Biotherapeutics Inc forecast:

Buy
57%
Hold
43%

Financial data from Atara Biotherapeutics Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
100 100
2,112% 2,112%
100%
- Direct Costs 17 17
4% 4%
17%
83 83
716% 716%
83%
- Selling and Administrative Expenses 34 34
25% 25%
34%
- Research and Development Expense 163 163
31% 31%
162%
-114 -114
59% 59%
-114%
- Depreciation and Amortization 5.16 5.16
62% 62%
5%
EBIT (Operating Income) EBIT -119 -119
59% 59%
-119%
Net Profit -133 -133
54% 54%
-133%

In millions USD.

Don't miss a Thing! We will send you all news about Atara Biotherapeutics Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Atara Biotherapeutics Inc Stock News

Neutral
Business Wire
15 days ago
THOUSAND OAKS, Calif.--(BUSINESS WIRE)---- $ATRA #CART--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced that the U.S. Food and Drug Administration (FDA) has placed a clinical hold on Atara's a...
More Atara Biotherapeutics Inc News

Company Profile

Atara Biotherapeutics, Inc. operates as a clinical stage company, which engages in the development of novel therapeutics for patients with cancer, autoimmune, and viral diseases. Its pipeline includes Tab-cel, ATA188, ATA2271/ATA3271, and ATA3219. The company was founded by Isaac E. Ciechanover on August 22, 2012 and is headquartered in South San Francisco, CA.

Head office United States
CEO Anhco Nguyen
Employees 225
Founded 2012
Website www.atarabio.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today